The short version of bremelanotide fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-08-20. Anything still debated is marked as such rather than presented as settled.
Bremelanotide is a synthetic cyclic heptapeptide developed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and appetite signalling. Its structure contains seven amino acid residues joined by a lactam bridge that closes the ring between two side chains. The molecular formula is C50H68N14O10 and the nominal molecular mass is near 1025 daltons. Much of the early laboratory literature refers to the same molecule by the development code PT-141.
The compound emerged from a research programme examining melanocortin analogues for effects on skin pigmentation. During early human studies, participants reported spontaneous erections as an unexpected side effect, which redirected development toward sexual function rather than tanning. An intranasal formulation was investigated in clinical trials but did not reach market approval. A subcutaneous injectable version later completed the regulatory process, and the nasal route does not appear in approved labelling.
After subcutaneous administration, plasma concentrations rise within roughly thirty minutes and the elimination half-life is short, on the order of two to three hours. Reported physiological responses include transient increases in blood pressure and nausea, which tended to diminish with repeated dosing in trial settings. Because the peptide clears quickly, effects are not expected to persist long after a dose. Absorption from non-injected routes is poorly characterised, and nasal delivery produced variable plasma levels in older work.
Clinical research typically uses randomised, double-blind, placebo-controlled designs. The most common primary endpoint is the desire domain score of the Female Sexual Function Index, sometimes paired with a distress measure. Secondary outcomes include arousal, satisfaction, and event-based counts of satisfying sexual episodes. Across trials, average improvements are modest and individual responses vary widely. Whether benefits persist beyond a few months, and whether they depend on baseline hormone status, remain open questions rather than settled findings.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H68N14O10 | Cyclic heptapeptide backbone |
| Molecular mass | Approximately 1025 Da | Nominal mass of the free peptide |
| Appearance | White to off-white lyophilised powder | Typical for purified synthetic peptides |
| Solubility class | Freely soluble in water | Organic solubility is limited |
| Typical storage temperature | −20 °C or below | Protect from moisture and light |
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.
Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.
Compared with melanotan II, bremelanotide is a smaller cyclic peptide with a more constrained backbone, which affects receptor selectivity and metabolic stability. Published descriptions give a plasma half-life on the order of a few hours after subcutaneous administration, with elimination through hepatic and renal routes and limited plasma protein binding. Central access is inferred from effects observed in animal models, although direct measurement in humans is limited. Handling and storage requirements follow from the peptide backbone, which is susceptible to hydrolysis and oxidation.
The melanocortin system comprises five G protein-coupled receptors, designated MC1 through MC5, that signal mainly through cyclic AMP accumulation. MC1R and MC2R are associated with pigmentation and adrenal steroid production, while MC3R and MC4R are expressed in the central nervous system and influence energy balance and behavior. MC5R appears in exocrine tissues. Natural agonists include alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone, and endogenous antagonists such as agouti-related protein modulate the same sites. This receptor family provides the framework within which bremelanotide activity is described.
Mary Brown's operated mainly in Newfoundland (about 20 locations with 2 locations in Halifax and 1 in Ontario) until the late 1970s, when it began expanding in Ontario, Alberta and Nova Scotia. In 2010, there were 38 locations in Newfoundland and Labrador, 30 locations in Ontario, 12 in Alberta and 3 in Nova Scotia, for an approximate total of 83. As of 2017, Mary Brown's has expanded into the United States, specifically in Florida. Drive-through and delivery services are available at some locations. The restaurant chain, started by Newfoundlanders Pat Tarrant and Cyril Fleming in 1969, was named after Mary Brown, the wife of a fried chicken recipe creator. The headquarters are in Markham, Ontario.
=== Hygiene and absorbent products === Applications in this field include: super water absorbent material (e.g. for incontinence pads material), nanocellulose used together with super absorbent polymers, nanocellulose in tissue, non-woven products or absorbent structures and as antimicrobial films.
=== Objective list theories === Objective list theories state that a person's well-being depends on several factors. These factors can include subjective components, like pleasure and desire-satisfaction, but also encompass objective factors that enhance a person's well-being independent of whether they subjectively care about them. Objective list theorists have proposed diverse lists of items to cover a wide variety of elements contributing to well-being, such as health, friendship, achievement, knowledge, and autonomy. Some versions argue that each element on the list is valuable by itself, while others hold that they complement each other and only promote well-being when combined. One criticism of objective list theories asserts that they define an incoherent concept of well-being by including diverse elements that have little in common. Another objection challenges the proposed objectivity of objective list theories, arguing that well-being is essentially a subjective phenomenon. According to this view, what is good for a person depends on their subjective attitude, and imposing an external definition of what is good leads to alienation.
=== The Adventures of Professor D === In 2026, Ariely published a children's graphic novel titled Professor D Takes Control, illustrated by Omer Hoffman. It is the first in a planned three-part series. The book is about a character named Professor D, who "gets into all kinds of trouble" and "uses social science" to get out of it.
Sources: en.wikipedia.org
Leach testified that through her role Fred had gradually begun to view her as a confidante and had confided in her that on the evening prior to his 25 February arrest he and Rose had formed a pact whereby he would take full responsibility for all the murders, many of which he had described to her as being "some of Rose's mistakes." Fred had further divulged that Rose had indeed murdered Charmaine while he had been incarcerated, and had also murdered Robinson. He had also confided that Rose had participated in the mutilation and dismemberment of Robinson, having personally removed the foetus from Robinson's womb after her death. In reference to the remaining eight murders for which Rose had been charged, Leach testified Fred had confided that Rose had "played a major part" in these murders. Upon cross-examination, Leach did concede to Ferguson she had earlier lied under oath about having sold her story to a national newspaper for £100,000, although she was adamant about the sincerity of her testimony. While delivering this testimony, Leach collapsed and the trial was adjourned for six days. She returned to complete her cross-examination on 13 November.
== Treatment == Stopping high vitamin A intake is the standard treatment. Most people fully recover. Phosphatidylcholine (in the form of PPC or DLPC), the substrate for lecithin retinol acyltransferase, which converts retinol into retinyl esters (the storage forms of vitamin A). Vitamin E may alleviate hypervitaminosis A. Liver transplantation may be a valid option if no improvement occurs. If liver damage has progressed into fibrosis, synthesizing capacity is compromised and supplementation can replenish PC. However, recovery is dependent on removing the causative agent: halting high vitamin A intake.
autozygote A cell or organism that is homozygous for a locus at which the two homologous alleles are identical by descent, both having been derived from a single gene in a common ancestor. Contrast allozygote.
=== Glyoxylate cycle === The glyoxylate cycle is a variant of the citric acid cycle. It is an anabolic pathway occurring in plants and bacteria utilizing the enzymes isocitrate lyase and malate synthase. Some intermediate steps of the cycle are slightly different from the citric acid cycle; nevertheless oxaloacetate has the same function in both processes. This means that oxaloacetate in this cycle also acts as the primary reactant and final product. In fact the oxaloacetate is a net product of the glyoxylate cycle because its loop of the cycle incorporates two molecules of acetyl-CoA.
Heseltine asked for his dissent to be minuted, and this was not done, although Cabinet Secretary Robert Armstrong stated that this had been an error and added it himself. On Monday 16 December Heseltine sat on the front bench with obvious disapproval when Brittan told the House that it was up to Westland to decide; on Wednesday 18 December he won the backing of the Commons Defence Committee for the European Consortium. On Thursday 19 December the matter was discussed at Cabinet for ten minutes: Cabinet approved leaving the decision to Westland and Heseltine was ordered to cease campaigning for the European option. Heseltine had failed to drum up enough support among possible allies like Tebbit, Howe, Walker, Norman Fowler and Tom King. A ministerial colleague at the time described him as "absolutely looney, completely hyped up with the thing" and of having a "persecution mania".
Sources: en.wikipedia.org
== Building blocks == Supramolecular systems are rarely designed from first principles. Rather, chemists have a range of well-studied structural and functional building blocks that they are able to use to build up larger functional architectures. Many of these exist as whole families of similar units, from which the analog with the exact desired properties can be chosen.
== Background == Porous inorganic solids have found great utility as catalysts and sorption media because of their large internal surface area, i.e. the presence of voids of controllable dimensions at the atomic, molecular, and nanometer scales. With increasing environmental concerns worldwide, nanoporous materials have become more important and useful for the separation of polluting species and the recovery of useful ones. In recent years there has been great progress in applying environmentally friendly zeolites in heterogeneous reaction catalysis. The reason for their success is related to their specific features in converting molecules having kinetic diameter below 1 nm, but they become inadequate when reactants with sizes above the dimensions of the pores have to be processed. Research efforts to synthesize zeolites with larger pore diameter, high structural stability and catalytic activity have not given the expected results yet.
Anorexia nervosa is highly heritable. Twin studies have shown a heritability rate of 28–58%. First-degree relatives of those with anorexia have roughly 12 times the risk of developing anorexia. Association studies have been performed, studying 128 different polymorphisms related to 43 genes including genes involved in regulation of eating behavior, motivation and reward mechanics, personality traits and emotion. Consistent associations have been identified for polymorphisms associated with agouti-related peptide, brain derived neurotrophic factor, catechol-o-methyl transferase, SK3 and opioid receptor delta-1. Epigenetic modifications, such as DNA methylation, may contribute to the development or maintenance of anorexia nervosa, though clinical research in this area is in its infancy. A 2019 study found a genetic relationship with mental disorders, such as schizophrenia, obsessive–compulsive disorder, anxiety disorder and depression; and metabolic functioning with a negative correlation with fat mass, type 2 diabetes and leptin.
Boletus edulis was first described in 1782 by the French botanist Pierre Bulliard and still bears its original name. The starting date of fungal taxonomy had been set as January 1, 1821, to coincide with the date of the works of the 'father of mycology', Swedish naturalist Elias Magnus Fries, which meant the name required sanction by Fries (indicated in the name by a colon) to be considered valid, as Bulliard's work preceded this date. It was thus written Boletus edulis Bull.:Fr. A 1987 revision of the International Code of Botanical Nomenclature set the starting date at May 1, 1753, the date of publication of Carl Linnaeus' Species Plantarum. Hence, the name no longer requires the ratification of Fries' authority. Early alternate names include Boletus solidus by English naturalist James Sowerby in 1809, and Gray's Leccinum edule. Gray's transfer of the species to Leccinum was later determined to be inconsistent with the rules of botanical nomenclature, and he apparently was unfamiliar with the earlier works of Fries when he published his arrangement of bolete species. Boletus edulis is the type species of the genus Boletus.
For type II and inverse type II dots, either the conduction or valence band of the core is located within the bandgap of the shell, which can lead to spatial separation of charge carriers in the core and shell. For all of these core/shell systems, the deposition of the outer layer can lead to potential lattice mismatch, which can limit the ability to grow a thick shell without reducing photoluminescent performance. One such reason for the decrease in performance can be attributed to the physical strain being put on the lattice. In a case where ZnSe/ZnS (type I) and ZnSe/CdS (type II) quantum dots were being compared, the diameter of the uncoated ZnSe core (obtained using TEM) was compared to the capped core diameter (calculated via effective mass approximation model) [lattice strain source] to better understand the effect of core-shell strain. Type I heterostructures were found to induce compressive strain and "squeeze" the core, while the type II heterostructures had the effect of stretching the core under tensile strain. Because the fluorescent properties of quantum dots are dictated by nanocrystal size, induced changes in core dimensions can lead to shifting of emission wavelength, further proving why an intermediate semiconductor layer is necessary to rectify lattice mismatch and improve quantum yield. One such core/double-shell system is the CdSe/ZnSe/ZnS nanocrystal. In a study comparing CdSe/ZnS and CdSe/ZnSe nanocrystals, the former was found to have PL yield 84% of the latter's, due to a lattice mismatch.
Sources: en.wikipedia.org
It is a synthetic cyclic peptide that acts as an agonist at melanocortin receptors. It is not a hormone replacement therapy and not a vasodilator in the usual clinical sense, although it does affect vascular tone. Chemically it belongs to the melanocortin analogue family.
PT-141 was the internal development code used during early research and it persists in older publications, conference abstracts, and informal listings. The code and the approved name refer to the same molecule. Its continued use reflects habit in the literature rather than any difference in substance.
No. The intranasal form was studied in trials but was never approved, and absorption through the nasal route varies considerably between individuals. Approved labelling covers a subcutaneous injection only. Any nasal product sold outside regulated channels falls outside verified manufacturing.
Trial results generally show a small to moderate average improvement in desire scores relative to placebo. The distribution of responses is wide, and some participants show little measurable change. Group averages should not be read as a prediction for any single person.